Glia-X™ Technology Plateform

  • Metabolic tests to characterize drugs in vitro (cell culture) and in vivo

  • Human induced-pluripotent cell derived (iPSC) brain cell and brain organoids models

  • High throughput screening (HTS)

  • New molecules design, optimization and development using in silico and in vitro target validation approaches

  • Proof of concepts realised using behavioural experiments

  • In vivo metabolic biomarkers (metabolites biosensors, fluorodeoxyglucose PET Scan)

Efficacy studies in preclinical neurological models (GLUT1 DS, Alzheimer’s disease, ALS, psychiatric diseases)